Paper33320447
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
Mveang Nzoghe A and 8 others. Immun Inflamm Dis, 2021. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. Papers, record 33320447. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33320447
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Cross Reactions | Major topic |
| Host-Pathogen Interactions | Major topic |
| Immunity, Humoral | Major topic |
| SARS-CoV-2 | Major topic |
| Adult | |
| Antibodies, Viral | |
| Female | |
| Humans | |
| Immunologic Memory | |
| Male | |
| Middle Aged | |
| Seroepidemiologic Studies |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| The Delegation of the European Union in Gabon, Sao Tome and Principe and ECCAS | PubMed | |||
| CHU-Mère-Enfant; Fondation Jeanne EBORI | PubMed |
Source PubMed
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23175507 | Pre-existing immunity against vaccine vectors--friend or foe? | Microbiology (Reading) | 2013 | https://conductscience.org/library/papers/23175507 | PubMed |
| 2 | 32747400 | Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2. | J Clin Microbiol | 2020 | https://conductscience.org/library/papers/32747400 | PubMed |
| 3 | 32814955 | Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. | Am J Clin Pathol | 2020 | https://conductscience.org/library/papers/32814955 | PubMed |
| 4 | 29978039 | Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. | Sci Adv | 2018 | https://conductscience.org/library/papers/29978039 | PubMed |
| 5 | 19745214 | Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19745214 | PubMed |
| 6 | 31508246 | Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. | NPJ Vaccines | 2019 | https://conductscience.org/library/papers/31508246 | PubMed |
| 7 | 33320447 | Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. | Immun Inflamm Dis | 2021 | https://conductscience.org/library/papers/33320447 | PubMed |
| 8 | 32213337 | Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. | Lancet Infect Dis | 2020 | https://conductscience.org/library/papers/32213337 | PubMed |
| 9 | 33397903 | Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. | Nat Commun | 2021 | https://conductscience.org/library/papers/33397903 | PubMed |
| 10 | 32808976 | Humoral Immune Response to SARS-CoV-2. | Am J Clin Pathol | 2020 | https://conductscience.org/library/papers/32808976 | PubMed |
| 11 | 32636479 | Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/32636479 | PubMed |
| 12 | 31160610 | M. tuberculosis infection and antigen specific cytokine response in healthcare workers frequently exposed to tuberculosis. | Sci Rep | 2019 | https://conductscience.org/library/papers/31160610 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39887249 | mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity. | J Virol | 2025 | https://conductscience.org/library/papers/39887249 | PubMed |
| 39198763 | Neopterin production in relation to COVID-19 in the Haut-Ogooué Province, Gabon. | BMC Infect Dis | 2024 | https://conductscience.org/library/papers/39198763 | PubMed |
| 39164256 | Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39164256 | PubMed |
| 38838076 | Time to SARS-CoV-2 clearance in African, Caucasian, and Asian ethnic groups. | Influenza Other Respir Viruses | 2024 | https://conductscience.org/library/papers/38838076 | PubMed |
| 37242383 | Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies. | Pathogens | 2023 | https://conductscience.org/library/papers/37242383 | PubMed |
| 37186902 | Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants. | Libyan J Med | 2023 | https://conductscience.org/library/papers/37186902 | PubMed |
| 36992136 | Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36992136 | PubMed |
| 36756213 | The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency. | Afr J Lab Med | 2023 | https://conductscience.org/library/papers/36756213 | PubMed |
| 36247198 | Covid-19: Early Cases and Disease Spread. | Ann Glob Health | 2022 | https://conductscience.org/library/papers/36247198 | PubMed |
| 35902675 | Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. | Sci Rep | 2022 | https://conductscience.org/library/papers/35902675 | PubMed |
| 35686525 | Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic. | J Zhejiang Univ Sci B | 2022 | https://conductscience.org/library/papers/35686525 | PubMed |
| 35373190 | The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue. | Front Trop Dis | 2021 | https://conductscience.org/library/papers/35373190 | PubMed |
| 34966142 | Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection. | Pediatr Infect Dis J | 2022 | https://conductscience.org/library/papers/34966142 | PubMed |
| 34615863 | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. | Nat Commun | 2021 | https://conductscience.org/library/papers/34615863 | PubMed |
| 34519768 | Demographic and Clinical Characteristics Associated With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/34519768 | PubMed |
| 34442823 | SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. | Microorganisms | 2021 | https://conductscience.org/library/papers/34442823 | PubMed |
| 34442723 | Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. | Microorganisms | 2021 | https://conductscience.org/library/papers/34442723 | PubMed |
| 34230895 | Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. | Transl Med Commun | 2021 | https://conductscience.org/library/papers/34230895 | PubMed |
| 34162141 | An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/34162141 | PubMed |
| 33853839 | Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic. | J Clin Microbiol | 2021 | https://conductscience.org/library/papers/33853839 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33320447
GET https://conductscience.org/api/papers/v1/33320447/cited_by?page=2